Linh Alejandro

Linh Alejandro

Company: Mirati Therapeutics Inc.

Job title: Medical Affairs Strategy GI Lead


Targeting KRAS Mutant Colorectal Cancer with a KRAS G12C Inhibitor: Current Status and Future Questions 10:30 am

History of targeting KRAS in the clinic and recent advancements to directly target KRAS G12C in CRC Clinical progress of KRAS G12C inhibitors (e.g. adagrasib) and treatment of patients with KRAS G12C mutated CRC Future questions and directions for targeting KRAS G12C in CRC, including combination strategiesRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.